Paclieva 260 mg contains Paclitaxel, a chemotherapy (anticancer) medicine from the taxane group. It acts by stabilizing microtubules, inhibiting their depolymerization, which blocks mitosis and results in cancer cell death.

Paclitaxel Injection is indicated for the treatment of:

1. Breast cancer

2. Ovarian cancer

3. Non-small cell lung cancer (NSCLC)

4. AIDS-related Kaposi’s sarcoma

5. Head and neck cancers (as part of combination chemotherapy)

Common side effects:

• Alopecia (hair loss)

• Nausea and vomiting

• Myelosuppression (neutropenia, anemia, thrombocytopenia)

• Fatigue, weakness

• Muscle and joint pain (myalgia, arthralgia)

• Peripheral neuropathy (numbness, tingling)

Dosage is individualized based on body surface area (BSA), cancer type, and treatment regimen.

Common dosing schedules:

• 175 mg/m² IV infusion over 3 hours every 3 weeks

• 135 mg/m² IV infusion over 24 hours every 3 weeks

• Weekly regimen: 80–100 mg/m² IV 

NOTE: This medicine should be taken only under a doctor’s supervision.